Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease
José Germán Sánchez‐Hernandez, Jonás Samuel Pérez‐Blanco, Noemí Rebollo, Fernándo Muñoz, Vanessa Prieto, María Victoria Martínez Calvo
Topics & Concepts
AdalimumabMedicineUlcerative colitisPharmacokineticsInflammatory bowel diseaseInternal medicinePopulationDosingTherapeutic drug monitoringGastroenterologyFaecal calprotectinInfliximabBiomarkerPharmacologyCalprotectinCrohn's diseaseDiseaseBiochemistryEnvironmental healthChemistryInflammatory Bowel DiseaseMicroscopic ColitisBiosimilars and Bioanalytical Methods